Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
Trial details
- Registry ID
- NCT04082364
- Phase
- Phase 2, Phase 3
The FDA approved margetuximab (MGAH22) on 16 Dec 2020.
Drug identity checked against registry records
Also recorded as MGAH22; Margenza®
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerNCT04082364 | MacroGenics | Phase 2, Phase 3 | Completed | 2024-01-15Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2020-12-16Day | margetuximab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA761150", "applicant_as_listed_by_fda": "TERSERA THERAPEUTICS LLC", "brand_names": ["MARGENZA"], "active_ingredients": ["MARGETUXIMAB-CMKB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20201216", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |